Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-004062-26
    Sponsor's Protocol Code Number:BAY1067197/17582
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2017-03-31
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2016-004062-26
    A.3Full title of the trial
    A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral partial adenosine A1 receptor agonist neladenoson bialanate over 20 weeks in patients with chronic heart failure and preserved ejection fraction
    Ensayo clínico de fase II, multicéntrico, aleatorizado, controlado con placebo, de grupos paralelos, doble ciego, de búsqueda de dosis para explorar los efectos farmacocinéticos y farmacodinámicos, la eficacia y la seguridad de bialanato de neladenosón, un agonista oral parcial del receptor de adenosina A1, durante 20 semanas, en pacientes con insuficiencia cardiaca crónica con fracción de eyección conservada
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    PANACHE - A phase II trial to study neladenoson bialanate over 20 weeks in patients with chronic heart failure with preserved ejection fraction
    PANACHE - Ensayo clínico fase II para estudiar el bialanato de neladenosón durante 20 semanas en pacientes con insuficiencia cardiaca crónica con fracción de eyección conservada
    A.4.1Sponsor's protocol code numberBAY1067197/17582
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBayer AG
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBayer AG
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBayer AG
    B.5.2Functional name of contact pointBayer Clinical Trials Contact
    B.5.3 Address:
    B.5.3.1Street Address.
    B.5.3.2Town/ cityBerlin
    B.5.3.3Post code13342
    B.5.3.4CountryGermany
    B.5.4Telephone number0034900102372
    B.5.6E-mailclinical-trials-contact@bayer.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBAY 1067197 hydrochloride film coated tablet 5 mg
    D.3.2Product code BAY 1067197 hydrochloride film coated tablet 5 mg
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNneladenoson bialanate
    D.3.9.2Current sponsor codeBAY 1067197
    D.3.9.3Other descriptive nameBAY 1067197
    D.3.9.4EV Substance CodeSUB32032
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBAY 1067197 hydrochloride film coated tablet 10 mg
    D.3.2Product code BAY 1067197 hydrochloride film coated tablet 10 mg
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNneladenoson bialanate
    D.3.9.2Current sponsor codeBAY 1067197
    D.3.9.3Other descriptive nameBAY 1067197
    D.3.9.4EV Substance CodeSUB32032
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBAY 1067197 hydrochloride film coated tablet 20 mg
    D.3.2Product code BAY 1067197 hydrochloride film coated tablet 20 mg
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNneladenoson bialanate
    D.3.9.2Current sponsor codeBAY 1067197
    D.3.9.3Other descriptive nameBAY 1067197
    D.3.9.4EV Substance CodeSUB32032
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    chronic heart failure with preserved ejection fraction (LVEF equal or above 45%)
    Insuficiencia cardiaca crónica con fracción de eyección conservada (FEVI >= 45 %)
    E.1.1.1Medical condition in easily understood language
    chronic heart failure with preserved ejection fraction
    Insuficiencia cardiaca crónica con fracción de eyección conservada
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.1
    E.1.2Level LLT
    E.1.2Classification code 10008908
    E.1.2Term Chronic heart failure
    E.1.2System Organ Class 100000004849
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Find the optimal dose of neladenoson bialanate for the Phase III trial by detecting and characterizing a significant dose-response relationship in the primary efficacy endpoint, absolute change from baseline in 6-minute walking distance (6MWD) at 20 weeks, in patients with chronic heart failure with preserved ejection fraction (HFpEF), and by characterizing the safety, tolerability, pharmacokinetic and pharmacodynamic effects of the compound when given in addition to appropriate therapy for specific co-morbidities
    Determinar la dosis óptima de bialanato de neladenosón para el estudio de fase III mediante la detección y evaluación de una relación dosis-respuesta significativa en el criterio principal de valoración, la variación absoluta respecto al periodo basal en la prueba de marcha de 6 minutos (PM6M) a las 20 semanas, en pacientes con insuficiencia cardíaca crónica con fracción de eyección conservada (IC-FEc), mediante la evaluación de la seguridad, la tolerabilidad y los efectos farmacodinámicos del compuesto cuando se administra junto al tratamiento adecuado para comorbilidades específicas
    E.2.2Secondary objectives of the trial
    An exploratory objective is to further assess pharmacokinetic parameters and blood and urine biomarkers.
    Un objetivo exploratorio es evaluar los parámetros farmacocinéticos y los
    biomarcadores en sangre y orina.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Men or women aged 45 years and older
    2. Diagnosis of chronic heart failure (CHF), NYHA class II-IV (without evidence of a non-cardiac explanation for dyspnea), LVEF ≥ 45% assessed by any imaging modality (e.g. echocardiography, cardiac magnetic resonance, cine levocardiography) within the previous 6 months with no significant change in clinical status suggesting potential for deterioration in ejection fraction.
    3. In the 6 months prior to run-in:
    a) Requirement of treatment with a diuretic
    AND
    b) Elevated natriuretic peptides, defined as one of:
    o BNP ≥ 75 pg/mL or NT-proBNP ≥ 300 pg/mL (sinus rhythm)
    o BNP ≥ 200 pg/mL or NT-proBNP ≥ 900 pg/mL (atrial fibrillation)
    AND
    c) At least one of the following:
    o LA enlargement (LA diameter ≥ 3.9 cm, LA volume ≥ 55 mL,
    LAVI ≥ 29 mL/m2, or LAA ≥ 20 cm2) (assessed by local imaging)
    o LV hypertrophy (septal or posterior wall thickness ≥ 1.1 cm) (local imaging)
    o Elevated filling pressures (invasive assessment) at rest (PAWP ≥ 20 mmHg or LVEDP ≥ 15 mmHg) or with exercise (PAWP ≥ 25 mmHg) (historical records)
    4. 6MWD ≥ 100 m and ≤ 550 m at Visit 2 (baseline)
    5. Written informed consent signed before any study-specific procedure
    1. Pacientes de ambos sexos de 45 años en adelante
    2. Diagnóstico de insuficiencia cardíaca crónica (ICC), clase II-IV de la NYHA (sin evidencia de explicación no cardíaca para la disnea), FEVI >= 45 % evaluada mediante cualquier técnica de diagnóstico por imagen (p. ej., ecocardiografía, resonancia magnética cardíaca, cinerradiografía, levocardiografía) en los 6 meses anteriores sin cambios significativos en el estado clínico que sugieran un posible deterioro de la fracción de eyección.
    3. En los 6 meses anteriores al período de preinclusión:
    a) Necesidad de tratamiento con un diurético
    Y
    b) Péptidos natriuréticos elevados, definidos de una de las siguientes maneras:
    o BNP >= 75 pg/ml o NT-proBNP >= 300 pg/ml (ritmo sinusal)
    o BNP >= 200 pg/ml o NT-proBNP >= 900 pg/ml (fibrilación auricular)
    Y
    c) Al menos una de las siguientes circunstancias:
    o Agrandamiento de AI (diámetro de AI >= 3,9 cm, volumen de AI >= 55 ml, IVAI >= 29 ml/m2, o AAI >= 20 cm2) (evaluado por diagnóstico por imagen local)
    o Hipertrofia de VI (grosor de pared septal o posterior >= 1,1 cm) (diagnóstico por imagen local)
    o Presiones de llenado elevadas (evaluación invasiva) en reposo (presión de enclavamiento pulmonar (PAWP) >= 20 mmHg o presión telediastólica VI (LVEDP) >= 15 mmHg) o con ejercicio (presión de enclavamiento pulmonar (PAWP) >= 25 mmHg) (registros históricos)
    4. PM6M >= 100 m y <= 550 m en la visita 2 (período basal)
    5. Consentimiento informado por escrito firmado antes de que se realice cualquier procedimiento específico del estudio.
    E.4Principal exclusion criteria
    1. Acute decompensated heart failure (defined as acute exacerbation of HF that may require IV therapy with diuretics, vasodilators or inotropic drugs and / or mechanical support) within the past 4 weeks
    2. Initiation or dose modification of cardiovascular pharmacological therapy within the past 2 weeks (dose modification of pre-existing diuretic / anticoagulant medication is allowed based on patient-specific needs)
    3. Inability to exercise: wheelchair / scooter / walker dependent; dependent on supplemental oxygen
    4. HF is not the primary factor limiting activity as indicated by the patient affirming #1, #2 or #3 of the following questionnaire:
    My ability to be active is most limited by:
    #1 - Joint, foot, leg, hip or back pain
    #2 - Unsteadiness or dizziness impairing daily mobility
    #3 - Lifestyle, weather, or I just don’t like to be active
    5. Previous diagnosis of HFrEF (LVEF < 40%)
    6. Known clinically significant persistent coronary ischemia (based on medical history, a preexisting or a recent clinical stress test)
    7. Occurrence of any of the following within 3 months:
    o Clinically evident myocardial infarction
    o Hospitalization for unstable angina
    o Stroke or transient ischemic attack
    o Coronary artery bypass graft (CABG)
    o Percutaneous coronary intervention (PCI)
    o Implantation of a cardiac resynchronization therapy device (CRTD)
    o Major surgery (that could interfere with patients’ ability to exercise)
    8. PCI, CABG or implantation of a CRTD planned between randomization and end of study
    9. Sustained systolic blood pressure ≤ 90 mmHg and / or signs and symptoms of hypotension prior to randomization
    10. Sustained systolic blood pressure ≥ 160 mmHg prior to randomization
    11. Sustained bradycardia with heart rate < 50 beats/minute or tachycardia with heart rate > 100 beats/minute prior to randomization
    12. Known clinically relevant ventricular arrhythmias (sustained ventricular tachycardia, ventricular flutter or fibrillation) within 3 months prior to randomization based on either medical history or device generated data (if applicable)
    13. Clinically relevant permanent or intermittent AV-block > grade II in patients without a permanent pacemaker or ICD / CRTD
    14. Severe uncorrected valvular heart disease
    15. Listing for heart transplantation and / or anticipated implantation of a ventricular assist device
    16. Severe pulmonary disease with any of the following:
    o Requirement of continuous (home) oxygen or
    o History of chronic obstructive pulmonary disease ≥ GOLD III
    o Use of systemic corticosteroids
    17. Asthma bronchiale with any of the following:
    o Symptoms not well-controlled within the past 6 months or
    o Ever intubated or in an intensive care unit for asthma
    18. Anemia with hemoglobin < 10 g/dL within 3 months prior to randomization. If several values are available the latest result should be used.
    19. Body mass index (BMI) > 45 kg/m2 at randomization
    20. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 calculated by Modification of Diet in Renal Disease (MDRD) formula within 3 months prior to randomization (see Appendix 16.1). If several values are available the latest result should be used.
    21. Hepatic insufficiency classified as Child-Pugh B or C (see Appendix 16.2), or any of the following:
    o Primary biliary cirrhosis (PBC)
    o Primary sclerosing cholangitis
    o PBC-autoimmune hepatitis overlap syndrome
    22. Concomitant use of any of the following therapy that cannot be discontinued:
    o Moderate or strong CYP3A4 inhibitors (Of note: grapefruit is a strong CYP3A4 inhibitor)
    o CYP3A4 inducers
    o Strong CYP2C8 inhibitors (Of note: clopidogrel is a strong CYP2C8 inhibitor)
    o Theophylline
    o Drugs having significant pre-systemic clearance via UGT1A1 in the intestine
    Respective substances must be stopped at least 7 days before randomization.
    1. Insuficiencia cardíaca descompensada aguda (definida como exacerbación aguda de la IC que puede requerir tratamiento i.v. con diuréticos, vasodilatadores o fármacos inotrópicos y/o apoyo mecánico) en las 4 semanas anteriores
    2. Inicio o modificación de la dosis de tratamiento farmacológico cardiovascular en las 2 semanas anteriores (se permite la modificación de la dosis de medicación diurética o anticoagulante preexistente según las necesidades específicas del paciente)
    3. Incapacidad para hacer ejercicio: dependiente de silla de ruedas / scooter / andador; dependiente de oxigenoterapia
    4. La IC no es el principal factor limitador de actividad, como indica el paciente al afirmar los números 1, 2 o 3 del siguiente cuestionario:
    Mi capacidad para estar activo está limitada sobre todo por:
    #1 - Dolor de articulaciones, pies, piernas, cadera o espalda
    #2 - Inestabilidad o mareos que limitan la movilidad cotidiana
    #3 - Estilo de vida, clima o simplemente no me gusta estar activo
    5. Diagnóstico previo de IC-FEr (FEVI < 40 %)
    6. Cardiopatía isquémica clínicamente significativa conocida persistente (según los antecedentes médicos o una prueba de esfuerzo previa o reciente)
    7. Aparición de cualquiera de las siguientes afecciones en los 3 meses previos:
    o Infarto de miocardio clínicamente evidente
    o Hospitalización por angina de pecho inestable
    o Ictus o accidente isquémico transitorio
    o Cirugía de bypass coronario
    o Intervención coronaria percutánea (ICP)
    o Implantación de un dispositivo de terapia de resincronización cardíaca (TRC)
    o Cirugía mayor (que podría afectar a la capacidad de hacer ejercicio de los pacientes)
    8. Previsión de ICP, cirugía de bypass coronario o implantación de un dispositivo de TRC entre la aleatorización y el final del estudio
    9. Presión arterial sistólica sostenida <= 90 mmHg y/o signos y síntomas de hipotensión antes de la aleatorización
    10. Presión arterial sistólica sostenida >= 160 mmHg antes de la aleatorización
    11. Bradicardia sostenida con una frecuencia cardíaca < 50 latidos/minuto o taquicardia con una frecuencia cardíaca > 100 latidos/minuto antes de la aleatorización
    12. Arritmias ventriculares clínicamente relevantes conocidas (taquicardia ventricular sostenida, flutter o fibrilación ventricular) en los 3 meses anteriores a la aleatorización según los antecedentes médicos o los datos generados por el dispositivo (si procede)
    13. Bloqueo AV permanente o intermitente >= grado II clínicamente relevante en pacientes sin un marcapasos permanente o un DCI/dispositivo TRC
    14. Enfermedad valvular cardiaca no corregida grave
    15. Pendiente de un trasplante cardíaco y/o previsión de la implantación de un dispositivo de asistencia ventricular
    16. Enfermedad pulmonar grave con cualquiera de las siguientes condiciones:
    o Necesidad continua de oxígeno (domiciliario) o
    o Antecedentes de enfermedad pulmonar obstructiva crónica ≥ GOLD III
    o Uso de corticoesteroides sistémicos
    17. Asma bronquial con cualquiera de las siguientes condiciones:
    o Síntomas de no estar bien controlada en los 6 meses anteriores o
    o Alguna intubación o ingreso en cuidados intensivos debido al asma
    18. Anemia con niveles de hemoglobina < 10 g/dl en los 3 meses anteriores a la aleatorización. Si hubiera varios valores disponibles, debe utilizarse el resultado más reciente.
    19. Índice de masa corporal (IMC) > 45 kg/m2 en la aleatorización
    20. Tasa de filtración glomerular estimada (TFGe) < 30 ml/min/1,73 m2 calculada mediante la fórmula MDRD (Modification of Diet in Renal Disease) en los 3 meses anteriores a la aleatorización. Si hubiera varios valores disponibles, debe utilizarse el resultado más reciente.
    21. Insuficiencia hepática clasificada como Child-Pugh B o C, o cualquiera de las siguientes condiciones:
    o Cirrosis biliar primaria (CBP)
    o Colangitis esclerosante primaria
    o Síndrome de sobreposición HAI/CBP
    22. Uso concomitante de cualquiera de los siguientes tratamientos que no se pueda suspender:
    o Inhibidores de CYP3A4 moderados o potentes (obsérvese que el pomelo es un inhibidor de CYP3A4 potente)
    o Inductores de CYP3A4
    o Inhibidores de CYP2C8 potentes (obsérvese que clopidogrel es un inhibidor de CYP2C8 potente)
    o Teofilina
    o Fármacos que tienen una depuración presistémica significativa a través de UGT1A1 en el intestino
    El tratamiento con las sustancias correspondientes deberá interrumpirse al menos 7 días antes de la aleatorización.
    E.5 End points
    E.5.1Primary end point(s)
    Absolute change from baseline in 6MWD after 20 weeks of treatment
    Variación absoluta respecto al período basal en PM6M tras 20 semanas de tratamiento
    E.5.1.1Timepoint(s) of evaluation of this end point
    at the end of the study, no formal interim analysis is planned
    Al final del estudio, no se prevé ningún análisis intermedio formal
    E.5.2Secondary end point(s)
    • Activity (e.g. duration, intensity) reported values and absolute change from baseline at 20 weeks
    • NT-proBNP (pg/mL), measured values (log transformed) and absolute / relative change from baseline at 20 weeks to assess elevated filling pressures
    • High sensitivity troponin T (hs-TNT; ng/L), measured values (log transformed) and absolute / relative change from baseline at 20 weeks as a biomarker of myocardial injury
    • KCCQ, as described in protocol Section 9.4.6.1, measured values and absolute / relative change from baseline
    • Actividad (por ejemplo, duración, intensidad) de los valores obtenidos y variación absoluta desde el período basal a las 20 semanas
    • NT-proBNP (pg/mL), valores medidos (log transformados) y variación absoluta/relativa respecto al periodo basal a las 20 semanas para evaluar las presiones de llenado elevadas
    • Troponina T de alta sensibilidad (hs-TNT; ng/L), valores medidos (log transformados) y variación absoluta/relativa respecto al periodo basal a las 20 semanas como biomarcador de lesión miocárdica
    • Cuestionario Kansas City (KCCQ), tal y como se describe en la Sección del protocolo 9.4.6.1, valores medidos y variación absoluta/relativa respecto al periodo basal
    E.5.2.1Timepoint(s) of evaluation of this end point
    At the end of the study, no formal interim analysis is planned
    Al final del estudio, no se prevé ningún análisis intermedio formal
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic Yes
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Biomarkers
    Biomarcadores
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial6
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA57
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Austria
    Belgium
    Bulgaria
    Germany
    Greece
    Israel
    Italy
    Japan
    Poland
    Portugal
    Spain
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study as a whole will be reached as soon as the last visit of the last patient has occurred in all centers in all participating countries (EU and non EU)
    El final del estudio en su conjunto se alcanzará en cuanto se haya realizado la última visita del último paciente en todos los centros de todos los países participantes (UE y no UE)
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days2
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days25
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 58
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 230
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state44
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 219
    F.4.2.2In the whole clinical trial 288
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-05-25
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-05-09
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-06-20
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 20:38:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA